A novel pharmaceutical agent is demonstrating significant promise in combating treatment-resistant hypertension and perhaps mitigating the progression of kidney disease, according to research unveiled September 17, 2025. The drug offers a potential breakthrough for millions worldwide struggling with persistently elevated blood pressure despite conventional therapies.
Hypertension, a leading cause of cardiovascular disease and kidney failure, affects an estimated 1.3 billion people globally. A significant subset-roughly 10-30%-experience treatment resistance, meaning standard medications fail to adequately control their blood pressure. This new development provides a potential lifeline for these individuals, reducing their risk of stroke, heart attack, and end-stage renal disease.Further studies are underway to fully elucidate the drug’s long-term effects and optimal patient selection criteria.
The medication works by [data not provided in source – omitted to avoid fabrication], offering a distinct mechanism of action compared to existing antihypertensive drugs. Clinical trial data, released September 17, 2025, indicate substantial reductions in systolic and diastolic blood pressure among patients with treatment-resistant hypertension. Researchers also observed encouraging signs of slowed kidney function decline in trial participants.
Citation: New drug lowers treatment-resistant high blood pressure and may slow kidney disease (2025, September 17) retrieved 17 September 2025 from https://medicalxpress.com/news/2025-09-drug-lowers-treatment-resistant-high.html
this document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
